ReviewNature communications2025
Economic and sustainable revolution to facilitate one-carbon biomanufacturing.
Review in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Engineering of fructose-6-phosphate aldolase for one-carbon conversion to mannitol in a designed biotransformation system.Synthetic and systems biotechnology · 2026Article
- Towards an enzyme cascade synthesis of the bulk chemical acrylic acid.Nature communications · 2026Article
- Tri-valorization of methanol in a single bioreactor: co-production of enzyme, chemical, and single-cell protein using engineered Pichia pastoris (Komagataella phaffii).Bioresources and bioprocessing · 2026Article
- Combining Electrochemical Reduction with Biosynthesis for Directed Conversion of COAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- An Unorthodox Enolate-Triggered Radical Relay Directs the Chemo Upgrading of Levulinic Acid Into Citramalic Acid.ChemSusChem · 2026Article
- Bioenergy carbon capture storage and utilization: a critical review of market dynamics and policy implications.Biotechnology for biofuels and bioproducts · 2026Review
- Demonstration and technoeconomic analysis of dodecanol production from acetate using metabolically engineered Escherichia coli.Metabolic engineering · 2026Article
- Methanol biotransformation for the production of biodegradable plastic monomer L-lactate in yeast.Nature communications · 2025Article
- A combined pseudouridine biomanufacturing platform enabled by a streamlined designer pathway.Nature communications · 2025Article
- A blueprint for designing the next-generation of synthetic CNature communications · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One-carbon (C1) biomanufacturing serves as a substitute for fossil-based feedstocks, aiming to de-fossilize chemical production and foster a circular carbon economy by recycling waste greenhouse gases. Here, we review the key economic and technical barriers associated with the commercialization of C1 biomanufacturing through case studies. Additionally, a viable roadmap to enhance cost competitiveness is unveiled, underscoring its potential to facilitate carbon neutrality as scalable and sustainable alternatives to traditional chemical production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.